hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06294236, orgStudyIdInfo id: SC291-102, briefTitle: Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM), statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2027-12, completionDateStruct date: 2028-03, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Sana Biotechnology, class: INDUSTRY, descriptionModule briefSummary: SC291-102 is a Phase 1 study to evaluate SC291 safety and tolerability, preliminary clinical response, cellular kinetics and exploratory assessments for subjects with severe autoimmune diseases., conditionsModule conditions: Lupus Erythematosus, conditions: Systemic Lupus Erythematosus, conditions: SLE (Systemic Lupus), conditions: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, conditions: Granulomatous Polyangiitis, conditions: Microscopic Polyangiitis, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: SC291, outcomesModule primaryOutcomes measure: Evaluate safety and tolerability of SC291, secondaryOutcomes measure: Evaluate preliminary clinical response to SC291, secondaryOutcomes measure: Evaluate preliminary clinical response to SC291, secondaryOutcomes measure: Evaluate preliminary clinical response to SC291, secondaryOutcomes measure: Evaluate preliminary clinical response to SC291, secondaryOutcomes measure: Evaluate preliminary clinical response to SC291 (LN and ERL Cohorts), secondaryOutcomes measure: Evaluate preliminary clinical response to SC291 (LN Cohort), secondaryOutcomes measure: Evaluate preliminary clinical response to SC291 (ERL Cohort), secondaryOutcomes measure: Evaluate preliminary clinical response to SC291 (AAV Cohort), secondaryOutcomes measure: Evaluate preliminary clinical response to SC291 (AAV Cohort), secondaryOutcomes measure: Evaluate cellular kinetics and persistence of SC291, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Swedish Medical Center, status: RECRUITING, city: Seattle, state: Washington, zip: 98122, country: United States, contacts name: Richie Satira, RN, role: CONTACT, phone: 206-386-2000, email: richard.satira@swedish.org, contacts name: Danna Caceres-Reyes, RN, role: CONTACT, phone: 206-386-2000, email: Danna.Caceres-Reyes@swedish.org, contacts name: Philip J. Mease, MD, MACR, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 47.60621, lon: -122.33207, hasResults: False
protocolSection identificationModule nctId: NCT06294223, orgStudyIdInfo id: SaglikBilU, briefTitle: Upper Extremity and Muscle Oxygenation, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2025-03-01, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Saglik Bilimleri Universitesi, class: OTHER, descriptionModule briefSummary: The aim of this study was to measure the acute change in oxygen saturation of skeletal muscle during resistance exercise in the upper extremity using near-infrared spectroscopy., conditionsModule conditions: Near-infrared Spectroscopy, conditions: Muscle Oxygenation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Exercise follow up with near-infrared spectroscopy, outcomesModule primaryOutcomes measure: Determination of Blood Pressure, primaryOutcomes measure: Saturation Measurement, primaryOutcomes measure: Muscle Oxygenation Measurement, primaryOutcomes measure: Determination of Heart Rate, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 30 Years, stdAges: ADULT, contactsLocationsModule locations facility: Saglik Bilimleri University, status: RECRUITING, city: Istanbul, zip: 34010, country: Turkey, contacts name: Esra Pehlivan, Ass Prof, role: CONTACT, phone: 05058527913, email: esra.pehlivan@sbu.edu.tr, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06294184, orgStudyIdInfo id: Guangzhou PH tDCS in SD, briefTitle: tDCS Interventions for Subthreshold Depressive Symptoms in Young Individuals., statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-01, primaryCompletionDateStruct date: 2024-11, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Guangzhou Psychiatric Hospital, class: OTHER_GOV, descriptionModule briefSummary: The purpose of this study is to assess the mechanisms of the effect of transcranial direct current stimulation (tDCS) in alleviating subthreshold depressive symptoms in young individuals, and individualized outcome prediction is carried out., conditionsModule conditions: Subthreshold Depression, conditions: Young People, conditions: Transcranial Direct Current Stimulation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: tdcs lDLPFC, interventions name: tdcs rVLPFC, interventions name: Sham, outcomesModule primaryOutcomes measure: The effect of tDCS in alleviating subthreshold depressive symptoms, secondaryOutcomes measure: Neuroaffective mechanisms of tDCS in alleviating subthreshold depressive symptoms, secondaryOutcomes measure: To predict the individual effect of tDCS in alleviating subthreshold depressive symptoms, eligibilityModule sex: ALL, minimumAge: 12 Years, maximumAge: 25 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Guangzhou Brain hospital(Guangzhou Huiai Hospital), status: RECRUITING, city: Guangzhou, state: Guangdong, zip: 510370, country: China, contacts name: Kangguang Lin, M.D;Ph.D, role: CONTACT, phone: 86-13560360144, email: klin@gzhmu.edu.cn, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06294171, orgStudyIdInfo id: Modified Alveolar Bone Cut, briefTitle: Efficacy of Modified Piezosurgery Alveolar Bone Cut With Osseodensification Drills in Expanding Narrow Alveolar Bone, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-11-15, primaryCompletionDateStruct date: 2023-05-01, completionDateStruct date: 2023-11-01, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: University of Baghdad, class: OTHER, descriptionModule briefSummary: The aim of the study is to determine the efficacy of modified piezosurgery with osseodensification drills in expanding narrow alveolar bone., conditionsModule conditions: Dental Implant Failed, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 14, type: ACTUAL, armsInterventionsModule interventions name: measurement of alveolar ridge width, outcomesModule primaryOutcomes measure: expansion rate, primaryOutcomes measure: expansion rate, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: University of Baghdad College of Dentistry, city: Baghdad, zip: 10011, country: Iraq, geoPoint lat: 33.34058, lon: 44.40088, hasResults: False
protocolSection identificationModule nctId: NCT06294106, orgStudyIdInfo id: 24-212, briefTitle: eTMS for Veterans and First Responders With PTSD, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-04, completionDateStruct date: 2026-04, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Virginia Polytechnic Institute and State University, class: OTHER, collaborators name: Wave Neuroscience, descriptionModule briefSummary: A battery of physiological and behavioral data will be collected before and after application of eTMS. Participants will be veterans or first responders diagnosed with PTSD. Study will be a double-blind, sham-controlled, parallel group, randomized clinical trial., conditionsModule conditions: Post Traumatic Stress Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: 10 participants will receive eTMS treatment 10 participants will receive sham eTMS treatment, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: DOUBLE, maskingDescription: eTMS coil will have an 'active' and 'sham' side and the application will look identical to the participant. The technician will not know which side of the coil is which and will additionally be blinded., whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Electroencephalogram personalized Transcranial Magnetic Stimulation (eTMS), outcomesModule primaryOutcomes measure: Adverse Events, primaryOutcomes measure: Report of Symptoms, secondaryOutcomes measure: PCL-5, eligibilityModule sex: ALL, minimumAge: 22 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fralin Biomedical Research Institute, city: Roanoke, state: Virginia, zip: 24016, country: United States, contacts name: Jessica Florig, MPH, role: CONTACT, phone: 540-526-2261, email: jnw@vtc.vt.edu, contacts name: Wynn Legon, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 37.27097, lon: -79.94143, hasResults: False
protocolSection identificationModule nctId: NCT06294093, orgStudyIdInfo id: 026/24, briefTitle: Differences Between Long Distance Road Runners and Treadmill Runners in Achilles Tendon Structure, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-02-15, completionDateStruct date: 2025-02-15, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: University of Haifa, class: OTHER, collaborators name: Zinman College of Physical Education and Sports Sciences, descriptionModule briefSummary: this study will investigate the structure of the Achilles tendon and functional tests in road runners compared to treadmill runners., conditionsModule conditions: Achilles Tendon Injury, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: ultrasound tissue characterized, primaryOutcomes measure: Balance test, primaryOutcomes measure: Proprioception test, primaryOutcomes measure: muscle strength test, primaryOutcomes measure: endurance test gastrocnemius muscle, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06294080, orgStudyIdInfo id: DfH2023, briefTitle: Effects of Dance and Tai Chi on Balance and Wellbeing on Healthy Adults, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09, primaryCompletionDateStruct date: 2024-11, completionDateStruct date: 2025-01, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: University of Wolverhampton, class: OTHER, descriptionModule briefSummary: The aim of the proposed randomised controlled study is to compare the effects and efficacy between a dance, a Tai Chi and a waiting list control group intervention over an eight-week period on physical functions and mental benefits among non-clinical adults aged between 18 and 59. The study's primary outcome is mental wellbeing and secondary parameters are physical functional and mood. A tertiary outcome will examine how the physical and mental parameters change during the learning and practice phases, conditionsModule conditions: General Population, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Random Controlled Trial: Blind, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: DOUBLE, maskingDescription: Data collection carried out by RAs blinded to participants' group allocation Statistician blinded to the group and test parameters, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 70, type: ESTIMATED, armsInterventionsModule interventions name: Dance, interventions name: Tai Chi, outcomesModule primaryOutcomes measure: Well-being, secondaryOutcomes measure: Leg strength, secondaryOutcomes measure: Balance, secondaryOutcomes measure: Mood, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 59 Years, stdAges: ADULT, contactsLocationsModule locations facility: University of Wolverhampton, city: Walsall, state: West Midlands, zip: WS1 3BD, country: United Kingdom, geoPoint lat: 52.58528, lon: -1.98396, hasResults: False
protocolSection identificationModule nctId: NCT06294054, orgStudyIdInfo id: 2021/0393/HP, briefTitle: Bladder Cancer and Neoadjuvant Chemotherapy Efficiency Before Cystectomy, acronym: SELECT, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-04-01, primaryCompletionDateStruct date: 2026-03-31, completionDateStruct date: 2026-03-31, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: University Hospital, Rouen, class: OTHER, collaborators name: Institut Curie, descriptionModule briefSummary: This study will allow the investigators to better assess the efficiency of neoadjuvant chemotherapy before cystectomy by training a predictive model on different patient cohorts with bladder cancer., conditionsModule conditions: Bladder Cancer, conditions: Genomic Instability, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 707, type: ESTIMATED, armsInterventionsModule interventions name: neoadjuvant chemotherapy with cisplatine, outcomesModule primaryOutcomes measure: Progression-free survival, secondaryOutcomes measure: Overall survival, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Centre de lutte contre le cancer François Baclesse, city: Caen, country: France, geoPoint lat: 49.18585, lon: -0.35912, locations facility: Centre de recherche des Cordeliers, city: Paris, country: France, geoPoint lat: 48.85341, lon: 2.3488, locations facility: Hôpital Saint-Louis AP-HP, city: Paris, country: France, geoPoint lat: 48.85341, lon: 2.3488, locations facility: Institut Curie Centre de Recherche, city: Paris, country: France, geoPoint lat: 48.85341, lon: 2.3488, locations facility: Institut Curie, city: Paris, country: France, geoPoint lat: 48.85341, lon: 2.3488, locations facility: Institut Gustave Roussy, city: Paris, country: France, geoPoint lat: 48.85341, lon: 2.3488, locations facility: Mines ParisTech, city: Paris, country: France, geoPoint lat: 48.85341, lon: 2.3488, hasResults: False
protocolSection identificationModule nctId: NCT06294028, orgStudyIdInfo id: RC31/21/0338, briefTitle: International Multicenter Project Comparing Radiofrequency Ablation Versus Implantable Defibrillator After Well-tolerated Ventricular Tachycardia in Ischemic Heart Disease With Minimally Impaired Ejection Fraction, acronym: VIVA, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2029-12-31, completionDateStruct date: 2029-12-31, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: University Hospital, Toulouse, class: OTHER, descriptionModule briefSummary: Evidence for the usefulness of the defibrillator in cases of preserved left ventricular ejection fraction and well-tolerated ventricular tachycardia (without cardiocirculatory arrest or syncope) is lacking, as no previous trials have included such patients. Additionally, sudden death in this particular population is low compared to other subgroups of patients with malignant ventricular arrhythmias.On the other hand, numerous recent retrospective data show that ablation of ventricular tachycardia can reduce mortality, and also clearly reduces the number of recurrences in prospective studies.Finally, a very low rate of sudden death was observed in a multicenter European retrospective study that we conducted, including patients with well-tolerated ventricular tachycardia in structural heart disease with minimally impaired ejection fraction and benefiting from ablation without implantation of defibrillator., conditionsModule conditions: Ischemic Heart Disease, conditions: Ventricular Tachycardia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 268, type: ESTIMATED, armsInterventionsModule interventions name: Adverse events collection, interventions name: Quality of life questionnaire EQ-5D-5L, interventions name: Medical-economic evaluation, outcomesModule primaryOutcomes measure: Monitoring for the occurrence of at least one serious event during the 36 months of follow-up, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06294015, orgStudyIdInfo id: 2023-5009, briefTitle: Efficacy of 20% Autologous Serum Drops in the Treatment of Corneal Epitheliopathy Associated With Antihypertensive Glaucoma Drops., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2026-04, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Université de Sherbrooke, class: OTHER, descriptionModule briefSummary: Introduction: Glaucoma is the second leading cause of blindness globally. Most anti-hypertensive drops contain preservatives harmful to the corneal epithelium, with up to 78% of treated patients reporting dry eye symptoms. Autologous serum eye drops (ASED), contains essential growth factors and nutrients which may promote corneal and conjunctival integrity, offering benefits over traditional treatments. This study investigates the efficacy of 20% ASED over placebo in the treatment of corneal epitheliopathies in patients with glaucoma treated with antihypertensive drops.Methods: The present study is a triple-blinded, randomized controlled trial that anticipates to enroll 25 patients (50 eyes) with bilateral corneal epitheliopathy secondary to antihypertensive glaucoma treatments. Patients will receive autologous serum eye drops in one eye and placebo in the contralateral eye for two months, in addition to standard artificial tears treatment.The primary outcome is the comparison of National Eye Institute (NEI) scores between autologous serum drops and placebo-treated eyes at two months. Secondary outcomes include Schirmer's test scores, visual acuity, tear break-up time (TBUT), Ocular Surface Disease Index (OSDI) scores, intraocular pressure, and complication rates.The study aims to analyze the effectiveness of autologous serum eye drops in treating corneal epitheliopathies in glaucoma patients, potentially offering a new therapeutic avenue., conditionsModule conditions: Corneal Epitheliopathy, conditions: Glaucoma, conditions: Corneal Disease, conditions: Dry Eye, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 25, type: ESTIMATED, armsInterventionsModule interventions name: 20% ASED + AT, interventions name: 0.9% NS + AT, outcomesModule primaryOutcomes measure: National Eye Index Scores, secondaryOutcomes measure: Schirmer Test, secondaryOutcomes measure: Visual Acuity, secondaryOutcomes measure: Tear Break Up Time, secondaryOutcomes measure: Ocular Surface Disease Index, secondaryOutcomes measure: Intraocular Pressure, secondaryOutcomes measure: Complication rates, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06293989, orgStudyIdInfo id: Emergency department, briefTitle: Efficacy and Safety of Intravenous Diazepam Given at 2 Different Doses Compared to Placebo in Acute Peripheral Vertigo, acronym: Vertigo, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-12-30, completionDateStruct date: 2026-03-30, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: University of Monastir, class: OTHER, descriptionModule briefSummary: This is prospective, randomised double-blind study that will be conducted in the emergency department of 3 university hospitals (FB Monastir, Sahloul Sousse, and FH Sousse) to compare the efficacy of two doses of diazepam (Valium®) and placebo for the relief of acute periphery vertigo in the ED, conditionsModule conditions: Vertigo, Peripheral, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule interventions name: Diazepam 5mg, interventions name: Diazepam 10 mg, interventions name: Placebo, outcomesModule primaryOutcomes measure: Visual analogue scale (VAS)-3H, secondaryOutcomes measure: the Delta-VAS, secondaryOutcomes measure: the time required to reach the resolution of the vertigo crisis, secondaryOutcomes measure: Patients satisfaction, secondaryOutcomes measure: number of patients with adverse effects, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False